HK inno.N to release K-CAB in MENA market

South Korean bio-health company HK inno.N announced on Tuesday that it signed a contract with Saudi Arabian local pharmaceutical company Tabuk Pharm...

HK inno.N reveals differentiated clinical results for K-CAB

South Korean bio-health company HK inno.N has been expanding its market by steadily announcing differentiated clinical results for its gastroesophag...

HK inno.N releases K-Cab in Singapore

South Korean bio-health company HK inno.N announced on Monday that it has released the new drug K-CAB for gastroesophageal reflux disease (GERD) in ...

Daewoong launches GERD treatment Fexuclu in Philippines

South Korea's Daewoong Pharmaceutical announced on Tuesday that it has launched the GERD treatment drug "Fexuclue" (active ingredient: Fexuprazan) i...

HK inno.N releases new drug for GERD in Indonesia

South Korean bio-health company HK inno.N Corporation's new drug for gastroesophageal reflux disease (GERD) K-CAB has been officially launched in In...

Daewoong wins approval for GERD treatment Fexuclu in Chile

South Korean pharmaceutical company Daewoong Pharmaceutical announced on Tuesday that it has received marketing authorization from Chile's National ...

HK inno.N's GERD drug K-CAB gets approval in Mexico

South Korea's biohealth company HK inno.N said on Tuesday that its gastroesophageal reflux disease (GERD) treatment K-CAB (active ingredient: tegopr...

Daewoong receives approval for its GERD drug Fexuclue in Ecuador

Daewoong Pharmaceutical said Friday that it has obtained marketing authorization from Ecuador's National Agency for Health Regulation, Control and S...

Daewoong submits new drug applications for Fexuclue in 10 countries

South Korea's leading drug company Daewoong Pharmaceutical is accelerating its global expansion efforts for its 34th domestically developed drug Fex...